Source: http://www.google.com/patents/US5935820?dq=7,328,163
Timestamp: 2016-07-24 04:10:13
Document Index: 522821396

Matched Legal Cases: ['application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 60']

Patent US5935820 - Polynucleotides encoding vascular endothelial growth factor 2 - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe present invention relates to polynucleotides encoding a novel human protein called Vascular Endothelial Growth Factor 2, or VEGF-2, as well as mature forms, proproteins, and fragments of VEGF-2. Also provided are vectors, host cells, and recombinant methods for producing VEGF-2. The invention further...http://www.google.com/patents/US5935820?utm_source=gb-gplus-sharePatent US5935820 - Polynucleotides encoding vascular endothelial growth factor 2Advanced Patent SearchPublication numberUS5935820 APublication typeGrantApplication numberUS 08/824,996Publication dateAug 10, 1999Filing dateMar 27, 1997Priority dateMar 8, 1994Fee statusLapsedAlso published asCA2184584A1, CA2184584C, CA2414016A1, CN1145636A, CN1267550C, DE69434538D1, DE69434538T2, EP0751992A1, EP0751992A4, EP0751992B1, US7498417, US20020182683, US20040214286, US20090192088, WO1995024473A1Publication number08824996, 824996, US 5935820 A, US 5935820A, US-A-5935820, US5935820 A, US5935820AInventorsJing-Shan Hu, Craig A. Rosen, Liang CaoOriginal AssigneeHuman Genome Science, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (8), Non-Patent Citations (23), Referenced by (167), Classifications (47), Legal Events (7) External Links: USPTO, USPTO Assignment, EspacenetPolynucleotides encoding vascular endothelial growth factor 2
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS5073492 *Jan 9, 1987Dec 17, 1991The Johns Hopkins UniversitySynergistic composition for endothelial cell growthUS5219739 *Jul 27, 1990Jun 15, 1993Scios Nova Inc.DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121US5326695 *May 15, 1992Jul 5, 1994Ludwig Institute For Cancer ResearchPlatelet derived growth factor agonistsEP0476983A1 *Sep 18, 1991Mar 25, 1992Merck &amp; Co., Inc.Vascular endothelial cell growth factor IIEP0506477A1 *Mar 27, 1992Sep 30, 1992Merck &amp; Co., Inc.Vascular endothelial cell growth factor C subunitWO1997005250A2 *Aug 1, 1996Feb 13, 1997Helsinki University Licensing Ltd. OyReceptor ligand vegf-cWO1997009427A1 *Aug 30, 1996Mar 13, 1997Genentech, Inc.Vegf-related proteinWO1997017442A1 *Nov 5, 1996May 15, 1997Immunex CorporationFlk-1 binding protein* Cited by examinerNon-Patent CitationsReference1 *Breier, G., et al., Development 114:521 532 (1992).2Breier, G., et al., Development 114:521-532 (1992).3 *Eichmann, A., et al., Development 125(4):743 752 (1998).4Eichmann, A., et al., Development 125(4):743-752 (1998).5 *Ferrara, et al., Journal of Cellular Biochemistry 47:211 218 (1991).6Ferrara, et al., Journal of Cellular Biochemistry 47:211-218 (1991).7 *George et al. Macromolecular Seq. and Syn. Selected Meth & Applic pp. 127 149, 1998.8George et al. Macromolecular Seq. and Syn. Selected Meth & Applic pp. 127-149, 1998.9 *Leung, D.W., et al., Science 246:1306 1309 (1989).10Leung, D.W., et al., Science 246:1306-1309 (1989).11 *Pajusola, K., et al., Cancer Research. 52:5738 5743 (1992).12Pajusola, K., et al., Cancer Research. 52:5738-5743 (1992).13 *Pajusola, K., et al., Oncogene 8:2931 2937 (1993).14Pajusola, K., et al., Oncogene 8:2931-2937 (1993).15 *Tischer, et al., Biochemical and Biophysical Research Communications 165(3):1198 1206 (1989).16Tischer, et al., Biochemical and Biophysical Research Communications 165(3):1198-1206 (1989).17 *U.S. application No. 08/340011, filed Nov. 1994.18 *U.S. application No. 08/510133, filed Aug. 1995.19 *U.S. application No. 08/585895, filed Jan. 1996.20 *U.S. application No. 08/601132, filed Feb. 1996.21 *U.S. application No. 08/671573, filed Jun. 1996.22 *U.S. application No. 08/8554374, filed Nov. 1995.23 *U.S. provisional application No. 60/03491, filed Sep. 1995.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS6130071 *Feb 5, 1997Oct 10, 2000Helsinki University Licensing, Ltd.Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereofUS6221839Aug 1, 1995Apr 24, 2001Helsinki University Licensing Ltd. OyFIt4 ligand and methods of useUS6245530Jan 12, 1996Jun 12, 2001Ludwig Institute For Cancer ResearchReceptor ligandUS6361946Feb 2, 1998Mar 26, 2002Licentia LtdVascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereofUS6403088Feb 14, 1996Jun 11, 2002Helsinki University Licensing, Ltd.Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)US6506884 *Mar 6, 2000Jan 14, 2003Compugen Ltd.Variant of vascular endothelial growth factorUS6576608May 17, 1999Jun 10, 2003Genentech, Inc.Methods of using VEGF-related proteinUS6608182Jun 6, 1995Aug 19, 2003Human Genome Sciences, Inc.Human vascular endothelial growth factor 2US6645933Jun 28, 1996Nov 11, 2003Helsinki University Licensing Ltd. OyReceptor ligand VEGF-CUS6730658Aug 2, 2000May 4, 2004Helsinki University Licensing, Ltd.Stimulation of lymphatic growth with an FLT4 ligandUS6734285Feb 28, 2002May 11, 2004Human Genome Sciences, Inc.Vascular endothelial growth factor 2 proteins and compositionsUS6818220Mar 24, 2000Nov 16, 2004Licentia Ltd.Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereofUS6887848Oct 10, 2002May 3, 2005Scios, Inc.Vascular endothelial growth factor variantsUS6958147Oct 26, 1999Oct 25, 2005Licentia LtdUse of VEGF-C to prevent restenosisUS6965010Feb 26, 2001Nov 15, 2005Licentia, Ltd.Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS6994989 *Nov 5, 1996Feb 7, 2006Immunex Corp.FLK-1 binding proteinsUS7026462Dec 6, 2001Apr 11, 2006Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS7034105Jan 19, 2001Apr 25, 2006Licentia, Ltd.FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapyUS7045133Jan 18, 2001May 16, 2006Ludwig Institute For Cancer ResearchVEGF-D/VEGF-C/VEGF peptidomimetic inhibitorUS7067317Apr 30, 2001Jun 27, 2006Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS7109308Dec 21, 2001Sep 19, 2006Human Genome Sciences, Inc.Antibodies to human vascular endothelial growth factor 2US7115392Apr 23, 2002Oct 3, 2006Human Genome Sciences, Inc.Polynucleotides encoding human vascular endothelial growth factor 2US7125714Jul 23, 2002Oct 24, 2006Licentia Ltd.Progenitor cell materials and methodsUS7125856Apr 11, 2000Oct 24, 2006St. Elizabeth's Medical Center Of Boston, Inc.Angiogenic growth factors for treatment of peripheral neuropathyUS7153827Dec 23, 1998Dec 26, 2006Human Genome Sciences, Inc.Vascular endothelial growth factor 2 and methods of useUS7153942Aug 24, 2001Dec 26, 2006Human Genome Sciences, Inc.Vascular endothelial growth factor 2US7186688Jun 30, 1998Mar 6, 2007Human Genome Sciences, Inc.Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2US7208582Apr 12, 2002Apr 24, 2007Human Genome Sciences, Inc.Vascular endothelial growth factor 2US7211240Mar 3, 2003May 1, 2007Bracco International B.V.Multivalent constructs for therapeutic and diagnostic applicationsUS7223724 *Feb 7, 2000May 29, 2007Human Genome Sciences, Inc.Use of vascular endothelial growth factor to treat photoreceptor cellsUS7227005Feb 25, 1999Jun 5, 2007Human Genome Sciences, Inc.Vascular endothelial growth factor 2US7261876Sep 11, 2003Aug 28, 2007Bracco International BvMultivalent constructs for therapeutic and diagnostic applicationsUS7273751Aug 3, 2001Sep 25, 2007Human Genome Science, Inc.Vascular endothelial growth factor-2US7309604Feb 24, 2005Dec 18, 2007Licentia, Ltd.Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS7329740Sep 14, 2005Feb 12, 2008Immunex CorporationFlk-1 binding proteinUS7358085Feb 28, 2006Apr 15, 2008Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS7402312Nov 19, 2004Jul 22, 2008Human Genome Sciences, Inc.Antibodies to vascular endothelial growth factor 2 (VEGF-2)US7423125Mar 3, 2004Sep 9, 2008Vegenics LimitedAntibodies to VEGF-CUS7439333Feb 28, 2005Oct 21, 2008Human Genome Sciences, Inc.Vascular endothelial growth factor 2US7498417May 26, 2004Mar 3, 2009Human Genome Sciences, Inc.Antibodies to vascular endothelial growth factor 2 and methods of using sameUS7524501Mar 14, 2005Apr 28, 2009Human Genome Sciences, Inc.Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodiesUS7560440Jul 14, 2006Jul 14, 2009Sangamo Bioschiences, Inc.Regulation of angiogenesis with zinc finger proteinsUS7566566Aug 28, 2007Jul 28, 2009Vengenics LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS7576189Aug 26, 2005Aug 18, 2009Human Genome Sciences, Inc.Antibodies to human vascular endothelial growth factor 2 and methods of using the sameUS7605140Apr 26, 2005Oct 20, 2009Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS7611711Nov 3, 2009Vegenics LimitedVEGFR-3 inhibitor materials and methodsUS7629145Dec 8, 2009Genentech, Inc.VEGF-related proteinUS7666979Feb 23, 2010Bracco International B.V.Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the sameUS7709270Oct 30, 2007May 4, 2010Vegenics Ltd.Vascular endothelial growth factor C (VEGF-C) protein diagnosticUS7727761Mar 3, 2004Jun 1, 2010Vegenics LimitedVascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereofUS7732196Dec 6, 2007Jun 8, 2010Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS7794693Sep 14, 2010Bracco International B.V.Targeting vector-phospholipid conjugatesUS7794756Oct 30, 2007Sep 14, 2010Vegenics LimitedMethods of using antibodies to VEGF-CUS7795209Sep 14, 2010Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS7807412Oct 30, 2007Oct 5, 2010Vegenies LimitedVEGF-C ΔR226ΔR227 mutants and uses thereofUS7829536Nov 9, 2010Vegenics LimitedMethod of treating lymphedema comprising administering VEGF-DUS7850963Dec 14, 2010Human Genome Sciences, Inc.Vascular endothelial growth factor 2US7854919Jan 19, 2007Dec 21, 2010Bracco, Suisse SAMultivalent constructs for therapeutic and diagnostic applicationsUS7893022Oct 31, 2007Feb 22, 2011Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS7902149Apr 10, 2009Mar 8, 2011Vegenics Pty LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS7910088Mar 21, 2007Mar 22, 2011Bracco Suisse SaMultivalent constructs for therapeutic and diagnostic applicationsUS7985402Dec 11, 2007Jul 26, 2011Bracco Suisse SaTargeting vector-phospholipid conjugatesUS8012946Sep 6, 2011Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS8044175Oct 25, 2011Dyax Corp.Peptides that specifically bind HGF receptor (CMET) and uses thereofUS8071564Sep 3, 2009Dec 6, 2011Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS8206708Jun 26, 2012Human Genome Sciences, Inc.Vascular endothelial growth factor 2US8216569Oct 31, 2007Jul 10, 2012Human Genome Sciences, Inc.Vascular endothelial growth factor 2US8278098Oct 2, 2012Vegenics Pty LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS8282931Oct 9, 2012Vegenics Pty LimitedVascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereofUS8357669Jan 22, 2013Vegenics Pty LimitedMethod of treatment for lymphedema comprising administering a polynucleotide encoding VEGF-DUS8455453Jun 4, 2013Vegenics Pty LtdUse of VEGF-D gene to prevent restenosisUS8551450May 19, 2010Oct 8, 2013Philippe BussatTargeting vector-phospholipid conjugatesUS8623822Oct 5, 2010Jan 7, 2014Bracco Suisse SaKDR and VEGF/KDR binding peptides and their use in diagnosis and therapyUS8632753Dec 20, 2010Jan 21, 2014Bracco Suisse SaMultivalent constructs for therapeutic and diagnostic applicationsUS8637262Oct 5, 2012Jan 28, 2014Vegenics Pty LimitedVascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereofUS8642010Jun 8, 2009Feb 4, 2014Dyax Corp.KDR and VEGF/KDR binding peptides and their use in diagnosis and therapyUS8663603Sep 23, 2010Mar 4, 2014Bracco Suisse SaMultivalent constructs for therapeutic and diagnostic applicationsUS8784809Jan 24, 2013Jul 22, 2014Human Genome Sciences, Inc.Vascular endothelial growth factor 2US8940695Jan 6, 2006Jan 27, 2015Vegenics Pty LimitedFlt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapyUS9000124Jul 14, 2011Apr 7, 2015Dyax Corp.Peptides that specifically bind HGF receptor (cMet) and uses thereofUS9056138Sep 19, 2013Jun 16, 2015Bracco Suisse SaMultivalent constructs for therapeutic and diagnostic applicationsUS9260526Nov 17, 2014Feb 16, 2016Vegenics Pty LimitedFlt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapyUS9295737Feb 26, 2014Mar 29, 2016Bracco Suisse SaTargeting vector-phospholipid conjugatesUS9381258Jul 23, 2013Jul 5, 2016Bracco Suisse S.A.Targeting vector-phospholipid conjugatesUS20020120123 *Apr 23, 2002Aug 29, 2002Human Genome Sciences, Inc.Human vascular endothelial growth factor 2US20020151680 *Feb 26, 2001Oct 17, 2002Kari AlitaloMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS20020164667 *Jan 15, 2002Nov 7, 2002Kari AlitaloVEGFR-3 inhibitor materials and methodsUS20020182683 *Feb 1, 2002Dec 5, 2002Human Genome Sciences, Inc.Vascular endothelial growth factor 2US20030008357 *Aug 24, 2001Jan 9, 2003Jing-Shan HuVascular endothelial growth factor 2US20030021776 *Dec 6, 2001Jan 30, 2003Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS20030044404 *Apr 30, 2001Mar 6, 2003Edward RebarRegulation of angiogenesis with zinc finger proteinsUS20030091567 *Jul 23, 2002May 15, 2003Kari AlitaloProgenitor cell materials and methodsUS20030096754 *Oct 10, 2002May 22, 2003Pollitt N. StephenVascular endothelial growth factor variantsUS20030113324 *Sep 30, 2002Jun 19, 2003Kari AlitaloNeuropilin/VEGF-C/VEGFR-3 materials and methodsUS20030166873 *Jan 17, 2003Sep 4, 2003Genentech, Inc.VEGF-related proteinUS20030170786 *Apr 12, 2002Sep 11, 2003Rosen Craig A.Vascular endothelial growth factor 2US20030175274 *Apr 12, 2002Sep 18, 2003Rosen Craig A.Vascular endothelial growth factor 2US20030215921 *Aug 3, 2001Nov 20, 2003Timothy ColemanVascular endothelial growth factor-2US20040018974 *Mar 3, 2003Jan 29, 2004Christophe ArbogastMultivalent constructs for therapeutic and diagnostic applicationsUS20040063656 *Sep 12, 2003Apr 1, 2004Ferrell Robert E.Screening and therapy for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)US20040120950 *Dec 20, 2002Jun 24, 2004Kari AlitaloModulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritisUS20040143103 *Oct 30, 2003Jul 22, 2004Human Genome Sciences, Inc.Vascular endothelial growth factor 2US20040147448 *Mar 3, 2004Jul 29, 2004Kari AlitaloVascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereofUS20040147726 *Mar 3, 2004Jul 29, 2004Kari AlitaloVascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereofUS20040210041 *Sep 11, 2003Oct 21, 2004Christophe ArbogastMultivalent constructs for therapeutic and diagnostic applicationsUS20040213790 *Jun 2, 2004Oct 28, 2004Genentech, Inc.VEGF-related proteinUS20040214766 *Sep 23, 2003Oct 28, 2004Kari AlitaloVEGF-C or VEGF-D materials and methods for treatment of neuropathologiesUS20040241800 *Dec 31, 2003Dec 2, 2004Jue Rodney AlanVascular endothelial growth factor dimersUS20040248796 *Feb 4, 2004Dec 9, 2004Kari AlitaloVEGF-B and PDGF modulation of stem cellsUS20050027105 *Sep 11, 2003Feb 3, 2005Christophe ArbogastMultivalent constructs for therapeutic and diagnostic applicationsUS20050032697 *Jun 14, 2004Feb 10, 2005Kari AlitaloHeparin binding VEGFR-3 ligandsUS20050043235 *Jun 14, 2004Feb 24, 2005Kari AlitaloUse of VEGF-C or VEGF-D in reconstructive surgeryUS20050059117 *Nov 4, 2004Mar 17, 2005Human Genome Sciences, Inc.Vascular endothelial growth factor 2US20050100963 *Sep 11, 2003May 12, 2005Dyax CorporationKDR and VEGF/KDR binding peptides and their use in diagnosis and therapyUS20050119165 *Aug 13, 2004Jun 2, 2005Scios, Inc.Vascular endothelial growth factor dimersUS20050147555 *Aug 11, 2004Jul 7, 2005Hong FanMethods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the sameUS20050176103 *Feb 28, 2005Aug 11, 2005Human Genome Sciences, Inc.Vascular endothelial growth factor 2US20050181979 *Mar 14, 2005Aug 18, 2005Human Genome Sciences, Inc.Vascular endothelial growth factor-2US20050192429 *Nov 19, 2004Sep 1, 2005Rosen Craig A.Vascular endothelial growth factor 2US20050232921 *Nov 19, 2004Oct 20, 2005Rosen Craig AVascular endothelial growth factor 2US20050250700 *Sep 13, 2004Nov 10, 2005Sato Aaron KKDR and VEGF/KDR binding peptidesUS20050256050 *Jun 16, 2005Nov 17, 2005Human Genome Sciences, Inc.Vascular endothelial growth factor 2US20050256075 *Feb 24, 2005Nov 17, 2005Kari AlitaloUse of VEGF-C or VEGF-D gene or protein to prevent restenosisUS20050267024 *Feb 24, 2005Dec 1, 2005Ludwig Institute For Cancer ResearchMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS20050267062 *Apr 26, 2005Dec 1, 2005Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS20050287143 *Aug 26, 2005Dec 29, 2005Human Genome Sciences, Inc.Human vascular endothelial growth factor 2US20060014252 *Sep 14, 2005Jan 19, 2006Immunex CorporationFlk-1 binding proteinUS20060025331 *Sep 23, 2005Feb 2, 2006Human Genome Sciences, Inc.Vascular endothelial growth factor 2US20060057117 *Oct 14, 2005Mar 16, 2006Human Genome Sciences, Inc.Vascular endothelial growth factor 2US20060121025 *Feb 3, 2006Jun 8, 2006Genentech, Inc.VEGF-related proteinUS20060171907 *Mar 29, 2006Aug 3, 2006The Procter & Gamble CompanyOral care compositions providing enhanced whitening and stain preventionUS20060177901 *Jan 6, 2006Aug 10, 2006Ludwig Institute For Cancer ResearchFlt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapyUS20060210539 *Feb 28, 2006Sep 21, 2006Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS20060269548 *Jul 12, 2002Nov 30, 2006Kari AlitaloLymphatic endothelial cells materials and methodsUS20070036813 *Jun 29, 2006Feb 15, 2007Genentech, Inc.Vegf-related proteinUS20070072818 *Jul 14, 2006Mar 29, 2007Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS20070082848 *Nov 16, 2006Apr 12, 2007Licentia Ltd.VEGF-C or VEGF-D materials and methods for treatment of neuropathologiesUS20070141609 *Jan 3, 2007Jun 21, 2007Ludwig Institute For Cancer ResearchScreening and Therapy for Lymphatic Disorders Involving the FLT4 Receptor Tyrosine Kinase (VEGFR-3)US20070243139 *Jan 19, 2007Oct 18, 2007Bracco International B.V.Multivalent constructs for therapeutic and diagnostic applicationsUS20080058263 *Aug 28, 2007Mar 6, 2008Ludwig Institute For Cancer ResearchMaterials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and ProteinsUS20080107607 *Dec 8, 2006May 8, 2008Bracco International B.V.Targeting vector-phospholipid conjugatesUS20080108556 *Oct 31, 2007May 8, 2008Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS20080118469 *Oct 31, 2007May 22, 2008Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS20080118510 *Jan 14, 2008May 22, 2008James LeeVegf-related proteinUS20080147045 *Jul 24, 2007Jun 19, 2008Licentia Ltd.Use of VEGF-C or VEGF-D in Reconstructive SurgeryUS20080152594 *Dec 11, 2007Jun 26, 2008Philippe BussatTargeting vector-phospholipid conjugatesUS20080187523 *Dec 6, 2007Aug 7, 2008Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS20080188643 *Dec 13, 2007Aug 7, 2008Immunex Corporationflk-1 binding proteinUS20080213272 *Apr 3, 2008Sep 4, 2008James LeeVegf-related proteinUS20080241142 *Nov 29, 2007Oct 2, 2008Licentia Ltd.Neuropilin/VEGF-C/VEGFR-3 Materials and MethodsUS20080241152 *Oct 30, 2007Oct 2, 2008Kari AlitaloVascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses ThereofUS20080241153 *Oct 30, 2007Oct 2, 2008Kari AlitaloVascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses ThereofUS20080317723 *May 22, 2008Dec 25, 2008Vegenics LimitedLymphatic endothelial cells materials and methodsUS20090023224 *Apr 3, 2007Jan 22, 2009Rosen Craig AVascular endothelial growth factor 2US20090104198 *Oct 30, 2007Apr 23, 2009Kari AlitaloVascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereofUS20090191166 *Feb 5, 2009Jul 30, 2009Ferrell Robert EScreening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)US20090318352 *Dec 24, 2009Vegenics LimitedMaterials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and ProteinsUS20100093838 *Sep 3, 2009Apr 15, 2010Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS20100260672 *Oct 14, 2010Dyax Corp.Peptides that specifically bind hgf receptor (cmet) and uses thereofUS20100261875 *Oct 14, 2010Dyax Corp.Peptides that specifically bind HGF receptor (CMET) and uses thereofUS20110135649 *Sep 10, 2010Jun 9, 2011Vegenics Pty LimitedVascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses ThereofUS20110207664 *Aug 25, 2011Vegenics Pty LimitedMaterials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and ProteinsUS20110229466 *Sep 22, 2011Human Genome Sciences, Inc.Vascular endothelial growth factor 2EP2277528A2Apr 12, 2001Jan 26, 2011Vlaams Interuniversitair Instituut voor BiotechnologieUse of VEGF and homologues to treat neuron disordersEP2295070A1Apr 12, 2001Mar 16, 2011Vlaams Interuniversitair Instituut voor BiotechnologieUse of VEGF and homologues to treat neuron disordersEP2314614A1Feb 28, 2006Apr 27, 2011Sangamo BioSciences, Inc.Anti-angiogenic methods and compositionsWO2002011769A1 *Aug 3, 2001Feb 14, 2002Human Genome Sciences, Inc.Vascular endothelial growth factor 2* Cited by examinerClassifications U.S. Classification435/69.4, 435/243, 435/70.1, 530/399, 536/23.4, 536/23.51, 435/320.1, 435/325International ClassificationC07K16/24, A61P17/02, A61K48/00, C12N15/12, C12N15/63, C07H21/00, A61K39/235, C07K16/18, A61P17/06, A61K49/00, A61K39/00, C07H21/04, A61P9/14, C07K14/52, A61P35/00, C12P21/02, A61P29/00, A61K39/395, A61K38/27, C12N1/21, A61P3/10, A61P27/02, C12N1/19, C12N15/18, A61K38/55, A61P9/00, A61K38/00, A61P43/00, C07K14/475, C12N15/09, C12P21/08, C07K14/485, G01N33/53, C12N5/10Cooperative ClassificationA61K39/00, A61K38/00, C07K2319/00, C07K14/52European ClassificationC07K14/52Legal EventsDateCodeEventDescriptionDec 11, 1998ASAssignmentOwner name: HUMAN GENOME SCIENCES, INC., MARYLANDFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HU, JING-SHAN;ROSEN, CRAIG A.;CAO, LIANG;REEL/FRAME:009914/0313;SIGNING DATES FROM 19980724 TO 19980727Dec 26, 2000CCCertificate of correctionFeb 7, 2003FPAYFee paymentYear of fee payment: 4Feb 12, 2007FPAYFee paymentYear of fee payment: 8Mar 14, 2011REMIMaintenance fee reminder mailedAug 10, 2011LAPSLapse for failure to pay maintenance feesSep 27, 2011FPExpired due to failure to pay maintenance feeEffective date: 20110810RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services